Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

KPMW135, a Biosuperior CD3 Bispecific Version of Rituximab Created By a Novel Chemical Conjugation Technology Demonstrates Increased Anti-Tumor Activity By Adding T Cell-Mediated Cytotoxicity Activity to the Existing Mechanisms of Rituximab

Christian Vidal, PhD, Michael Cukan, PhD, Ada Vaill, MS, Anna Bunin, PhD, Ann Marie Rossi, MS, Lawrence Iben, MA, David Trinh, BS, Katy McGrath, BS, Tanya Berbasova, PhD, Rizwan Romee, MD, Enrique Alvarez, DVM, Luca Rastelli, PhD, Matthew Welsch, PhD

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-142113

Published: 2020

Journal Articles

A Novel Class of Bifunctional Immunotherapeutic That Exploits a Universal Antibody Binding Terminus (uABT) to Recruit Endogenous Antibodies to Cell Expressing CD38 Demonstrate In Vivo efficacy in Three Distinct Animal Models

Anna Bunin, PhD, Katy McGrath, BS, Ann Marie Rossi, MS, Matthew Welsch, PhD, Christian Vidal, PhD, David Trinh, BA, David Spiegel, MD, PhD, Luca Rastelli, PhD, Enrique Alvarez, DVM

Blood (2019) 134 (Supplement_1): 1820.

https://doi.org/10.1182/blood-2019-130838

Published: 2019

Journal Articles

A Novel Class of Bifunctional Immunotherapeutic That Exploit a Universal Antibody Binding Terminus (uABT) to Recruit Endogenous Antibodies to Cells Expressing CD38 Demonstrates Anti-Multiple Myeloma Activity in Vitro and Ex Vivo against Patient Tumor Cells

Ann Marie Rossi, MS, Anna Bunin, PhD, Lawrence Iben, BS, MA, Matthew Welsch, PhD, Tanya Berbasova, PhD, Caterina Riillo, Marco Rossi, Masaki Ohuchi, PhD, Enrique Alvarez, DVM, Naoko Kawakami, Takayuki Nagasawa, PhD, Pierfrancesco Tassone, MD, David Spiegel, MD, PhD, Luca Rastelli, PhD

Blood (2019) 134 (Supplement_1): 4411.

https://doi.org/10.1182/blood-2019-131794

Published: 2019

Journal Articles

Targeting MEK1/2 Signaling Cascade by AS703026, a Novel Selective MEK1/2 Inhibitor, Induces Pleiotropic Anti-Myeloma Activity in Vitro and In Vivo.

Yu-Tzu Tai, Ph.D., Kihyun Kim, M.D., Xian-Feng Li, M.S., Mariateresa Fulciniti, Ph.D., Weihua Song, M.D., Sabikun Nahar, B.S., Peter Burger, B.S., Mathew J. Rumizen, Klaus Podar, M.D., Ph.D., Dharminder Chauhan, Ph.D, Teru Hideshima, M.D., Ph.D., Robert L Schlossman, M.D., Ph.D., Nikhil C. Munshi, Paul Richardson, M.D., Ph.D., Ann Clark, Ph.D., Janet Ogden, Ph.D., Goutopoulos Andreas, Ph.D., Luca Rastelli, Ph.D., Kenneth C. Anderson, MD

Blood (2009) 114 (22): 3848.

https://doi.org/10.1182/blood.V114.22.3848.3848

Published: 2009

Journal Articles

The Transcriptional Signature of Kinases Inhibited by the Multi-Targeted Kinase Inhibitor AS703569 Is Associated with Clinical Outcome in Multiple Myeloma (MM): Anti-MM Activity of AS703569 in Preclinical Studies.

Jake Delmore, David N. Cervi, Douglas McMillin, Efstathios Kastritis, Jana Jakubikova, Melissa G. Ooi, Steffen Klippel, Joseph M. Negri, Leutz Buon, Jacob Laubach, Luca Rastelli, Ann Clark, Samantha M. Sarno, Paul G. Richardson, Kenneth C. Anderson, Constantine S. Mitsiades, M.D., Ph.D

Blood (2009) 114 (22): 730.

https://doi.org/10.1182/blood.V114.22.730.730

Published: 2009

NARROW

KPMW135, a Biosuperior CD3 Bispecific Version of Rituximab Created By a Novel Chemical Conjugation Technology Demonstrates Increased Anti-Tumor Activity By Adding T Cell-Mediated Cytotoxicity Activity to the Existing Mechanisms of Rituximab

A Novel Class of Bifunctional Immunotherapeutic That Exploits a Universal Antibody Binding Terminus (uABT) to Recruit Endogenous Antibodies to Cell Expressing CD38 Demonstrate In Vivo efficacy in Three Distinct Animal Models

A Novel Class of Bifunctional Immunotherapeutic That Exploit a Universal Antibody Binding Terminus (uABT) to Recruit Endogenous Antibodies to Cells Expressing CD38 Demonstrates Anti-Multiple Myeloma Activity in Vitro and Ex Vivo against Patient Tumor Cells

Targeting MEK1/2 Signaling Cascade by AS703026, a Novel Selective MEK1/2 Inhibitor, Induces Pleiotropic Anti-Myeloma Activity in Vitro and In Vivo.

The Transcriptional Signature of Kinases Inhibited by the Multi-Targeted Kinase Inhibitor AS703569 Is Associated with Clinical Outcome in Multiple Myeloma (MM): Anti-MM Activity of AS703569 in Preclinical Studies.

Email alerts

ASH Publications

American Society of Hematology

KPMW135, a Biosuperior CD3 Bispecific Version of Rituximab Created By a Novel Chemical Conjugation Technology Demonstrates Increased Anti-Tumor Activity By Adding T Cell-Mediated Cytotoxicity Activity to the Existing Mechanisms of Rituximab

A Novel Class of Bifunctional Immunotherapeutic That Exploits a Universal Antibody Binding Terminus (uABT) to Recruit Endogenous Antibodies to Cell Expressing CD38 Demonstrate In Vivo efficacy in Three Distinct Animal Models

A Novel Class of Bifunctional Immunotherapeutic That Exploit a Universal Antibody Binding Terminus (uABT) to Recruit Endogenous Antibodies to Cells Expressing CD38 Demonstrates Anti-Multiple Myeloma Activity in Vitro and Ex Vivo against Patient Tumor Cells

Targeting MEK1/2 Signaling Cascade by AS703026, a Novel Selective MEK1/2 Inhibitor, Induces Pleiotropic Anti-Myeloma Activity in Vitro and In Vivo.

The Transcriptional Signature of Kinases Inhibited by the Multi-Targeted Kinase Inhibitor AS703569 Is Associated with Clinical Outcome in Multiple Myeloma (MM): Anti-MM Activity of AS703569 in Preclinical Studies.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only